Skip to main content
Equibles
DFTX logo

DFTX · Definium Therapeutics, Inc. · Metrics

Track DFTX — free

Use DFTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DFTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$33.00 -1.47 (-4.26%) At close · Nov 12 Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$4.52B
Shares
136.90M
Volume · Nov 12 1.2M Avg daily vol (3M) 2M

DFTX metrics

59 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$33.00
Market cap
$4.52B

Price action

23 metrics
Price change (1W)
+5.4%
Price change (30D)
+0.3%
Price change (3M)
-19.4%
Price change (6M)
+56.6%
Price change (YTD)
+157.4%
Price change (1Y)
+176.2%
Trailing year
Price change (5Y)
—
52-week high
$48.45
52-week low
$10.68
Change from 52-week high
-28.9%
Change from 52-week low
+222.8%
Annualized volatility
77.7%
Annualized volatility (3M)
61.1%
Implied volatility (30D)
101.5%
IV rank (1Y)
48.8
IV percentile (1Y)
75.8
Beta
1.2
RSI (14D)
47.9
Price vs SMA 50
-5.1%
Price vs SMA 200
+13.9%
Avg volume (3M)
2.10M
Relative volume
0.7
Average dollar volume
$80.27M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
136.90M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
4.9
reciprocal yield 20.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-7.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-09

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$254.15M
Net income (TTM)
−$337.48M
Trailing 12 months
Diluted EPS (TTM)
$-3.04
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$3.36

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+59.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-34.9%
Return on assets
-31.4%
Debt / equity
0.0
Current ratio
15.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
15.5
Interest coverage
-51.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.01B
Latest balance sheet
Cash & equivalents
$241.15M
Total assets
$1.07B
Total debt
$36.66M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$191.36M
Capital expenditures (TTM)
—
R&D (TTM)
$169.81M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
363
13F filer change QoQ
+115
Institutional ownership
87.4%
Conviction holders (share of 13F filers)
3.6%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+51.4%
Holder tenure
1.9
Price vs estimated holder cost
+138.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
9.3%

Short interest

3 metrics
Short interest
7.0%
Latest settlement · 5.8 days to cover
Days to cover
5.8d
Short-squeeze score
67 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$3.02M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1813814 CUSIP 24477V105 13F (30d) 192 filings 190 filers Visit website Investor relations